Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

US Selumetinib Registry

NCT05683678 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05683678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05683678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
US Selumetinib Registry
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Observational
Overall status
Terminated
Start date
January 4, 2019
Completion date
November 13, 2024
Enrollment
37 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis type 1, plexiform neurofibromas